These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 8247304)

  • 21. Heparin and low-molecular-weight heparin therapy for venous thromboembolism: will unfractionated heparin survive?
    Hull RD; Pineo GF
    Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():11-23. PubMed ID: 15085462
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A survey of aPTT reporting in Canadian medical laboratories. The need for increased standardization. Thrombosis Interest Group of Canada.
    Brigden ML; Johnston M
    Am J Clin Pathol; 2000 Aug; 114(2):276-82. PubMed ID: 10941344
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inability of the activated partial thromboplastin time to predict heparin levels. Time to reassess guidelines for heparin assays.
    Baker BA; Adelman MD; Smith PA; Osborn JC
    Arch Intern Med; 1997 Nov; 157(21):2475-9. PubMed ID: 9385299
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activated clotting time differential is a superior method of monitoring anticoagulation following coronary angioplasty.
    Pitney MR; Kelly SA; Allan RM; Giles RW; McCredie M; Walsh WF
    Cathet Cardiovasc Diagn; 1996 Feb; 37(2):145-50. PubMed ID: 8808069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Two instruments to determine activated partial thromboplastin time: implications for heparin monitoring.
    Taylor CT; Petros WP; Ortel TL
    Pharmacotherapy; 1999 Apr; 19(4):383-7. PubMed ID: 10212007
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The impact of heparin bolus from dysfunctional lumen of dual lumen central venous catheter on activated partial thromboplastin time during hemodialysis: is additional heparinization necessary?].
    Sefer S; Kes P; Raić B; Heinrich B; Degoricija V; Szavits-Nossan J
    Acta Med Croatica; 2006 Jun; 60(3):281-5. PubMed ID: 16933844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Different effects of heparin in males and females.
    Campbell NR; Hull RD; Brant R; Hogan DB; Pineo GF; Raskob GE
    Clin Invest Med; 1998 Apr; 21(2):71-8. PubMed ID: 9562927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Monitoring of heparin therapy with activated recalcification time].
    Lutze G; Schlote A; Urbahn H
    Z Gesamte Inn Med; 1981 Feb; 36(4):102-6. PubMed ID: 7222858
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the activated partial thromboplastin time (APTT) sensitivity to heparin using five commercial reagents: implications for therapeutic monitoring.
    Manzato F; Mengoni A; Grilenzoni A; Lippi G
    Clin Chem Lab Med; 1998 Dec; 36(12):975-80. PubMed ID: 9915232
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of synthetic phospholipids on the response of the activated partial thromboplastin time to heparin.
    van den Besselaar AM; Neuteboom J; Bertina RM
    Blood Coagul Fibrinolysis; 1993 Dec; 4(6):895-903. PubMed ID: 8148482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monitoring unfractionated heparin with APTT: a French collaborative study comparing sensitivity to heparin of 15 APTT reagents.
    Gouin-Thibaut I; Martin-Toutain I; Peynaud-Debayle E; Marion S; Napol P; Alhenc-Gelas M;
    Thromb Res; 2012 May; 129(5):666-7. PubMed ID: 22169771
    [No Abstract]   [Full Text] [Related]  

  • 32. The effect of instrumentation and laboratory site on the accuracy of the APTT-based heparin therapeutic range.
    Marlar RA; Gausman JN
    Int J Lab Hematol; 2012 Dec; 34(6):614-20. PubMed ID: 22712447
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prolonged heparin administration during clopidogrel treatment in healthy subjects.
    Caplain H; D'Honneur G; Cariou R
    Semin Thromb Hemost; 1999; 25 Suppl 2():61-4. PubMed ID: 10440426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of the activated partial thromboplastin time for monitoring heparin therapy: problems and possible solutions.
    Poller L; Thomson JM; Taberner DA
    Ric Clin Lab; 1989; 19(4):363-70. PubMed ID: 2633304
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin.
    Anand S; Ginsberg JS; Kearon C; Gent M; Hirsh J
    Arch Intern Med; 1996 Aug 12-26; 156(15):1677-81. PubMed ID: 8694666
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new plastic collection tube made of polyethylene terephtalate is suitable for monitoring traditional anticoagulant therapy (oral anticoagulant, unfractionated heparin, and low molecular weight heparin).
    Toulon P; Ajzenberg N; Smahi M; Guillin MC
    Thromb Res; 2007; 119(2):135-43. PubMed ID: 16426667
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The optimum number and types of plasma samples necessary for an accurate activated partial thromboplastin time-based heparin therapeutic range.
    Marlar RA; Gausman J
    Arch Pathol Lab Med; 2013 Jan; 137(1):77-82. PubMed ID: 23276178
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A survey of heparin monitoring in Australasia.
    Mackinlay N; Favaloro E; Arthur C; Smith J; Aboud M
    Pathology; 1996 Nov; 28(4):343-7. PubMed ID: 9007954
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Laboratory monitoring of heparin therapy--the effect of different salts of heparin on the activated partial thromboplastin time.
    Banez EI; Triplett DA; Koepke J
    Am J Clin Pathol; 1980 Oct; 74(4 Suppl):569-74. PubMed ID: 7435450
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activated partial thromboplastin time.
    Ignjatovic V
    Methods Mol Biol; 2013; 992():111-20. PubMed ID: 23546708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.